Virginia Retirement Systems ET AL grew its holdings in Xencor Inc (NASDAQ:XNCR) by 6.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,700 shares of the biopharmaceutical company’s stock after purchasing an additional 1,600 shares during the quarter. Virginia Retirement Systems ET AL’s holdings in Xencor were worth $893,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. FMR LLC boosted its stake in Xencor by 0.4% during the 3rd quarter. FMR LLC now owns 8,373,916 shares of the biopharmaceutical company’s stock worth $326,331,000 after acquiring an additional 30,163 shares during the last quarter. Primecap Management Co. CA boosted its stake in Xencor by 0.7% during the 3rd quarter. Primecap Management Co. CA now owns 7,621,743 shares of the biopharmaceutical company’s stock worth $297,019,000 after acquiring an additional 54,800 shares during the last quarter. Vanguard Group Inc. boosted its stake in Xencor by 33.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,195,674 shares of the biopharmaceutical company’s stock worth $163,506,000 after acquiring an additional 1,040,578 shares during the last quarter. Vanguard Group Inc boosted its stake in Xencor by 33.0% during the 3rd quarter. Vanguard Group Inc now owns 4,195,674 shares of the biopharmaceutical company’s stock worth $163,506,000 after acquiring an additional 1,040,578 shares during the last quarter. Finally, BlackRock Inc. boosted its stake in Xencor by 1.0% during the 3rd quarter. BlackRock Inc. now owns 4,051,683 shares of the biopharmaceutical company’s stock worth $157,896,000 after acquiring an additional 40,528 shares during the last quarter. 82.44% of the stock is currently owned by institutional investors.
Get Xencor alerts:Shares of XNCR stock opened at $30.34 on Friday. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -28.90 and a beta of 1.60. Xencor Inc has a 52 week low of $27.57 and a 52 week high of $48.38.
Several research analysts recently weighed in on XNCR shares. Cantor Fitzgerald reissued a “buy” rating and set a $40.00 price objective on shares of Xencor in a research note on Tuesday, November 6th. Zacks Investment Research raised shares of Xencor from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research note on Friday, November 9th. BidaskClub raised shares of Xencor from a “hold” rating to a “buy” rating in a research note on Friday, November 23rd. Finally, Wedbush lifted their price objective on shares of Xencor from $42.00 to $44.00 and gave the stock an “outperform” rating in a research note on Friday, December 7th. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $42.00.
WARNING: This article was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4188090/virginia-retirement-systems-et-al-acquires-1600-shares-of-xencor-inc-xncr.html.
Xencor Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
See Also: Return on Investment (ROI) Defined, Explained
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).
No comments:
Post a Comment